Holen Sie sich die Stockscreener-App
180.02
0.17%
-0.2973
Schlusskurs vom Vortag:
$180.32
Offen:
$181.56
24-Stunden-Volumen:
304.56K
Relative Volume:
0.30
Marktkapitalisierung:
$11.09B
Einnahmen:
$4.27B
Nettoeinkommen (Verlust:
$-356.15M
KGV:
-30.15
EPS:
-5.9702
Netto-Cashflow:
$1.19B
1W Leistung:
-1.10%
1M Leistung:
+8.24%
6M Leistung:
+42.68%
1J Leistung:
+32.31%
1-Tages-Spanne:
$177.58
$183.90
1-Wochen-Bereich:
$177.58
$188.62
52-Wochen-Spanne:
$95.49
$198.00
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
180.10 | 11.10B | 4.27B | -356.15M | 1.19B | -5.9702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.55 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.82 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.63 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.89 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Eingeleitet | Barclays | Overweight |
| 2025-11-24 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-15 | Eingeleitet | Deutsche Bank | Buy |
| 2025-03-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Jazz Pharmaceuticals (JAZZ) Price Forecast: Multi-Year Base Signals Breakout Potential - FXEmpire
Jazz Pharmaceuticals at Barclays Conference: Strategic Growth Insights - Investing.com South Africa
Jazz Pharmaceuticals at Barclays Conference: Strategic Growth Insights By Investing.com - Investing.com UK
Capital World Investors Increases Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Record Revenue And Supportive Barclays Commentary - simplywall.st
Jazz Pharmaceuticals Stock at $185: Here’s Why Analysts See a New All-Time High in 2026 - TIKR.com
Jazz’s 2025 Net Loss and 2026 Outlook Might Change The Case For Investing In JAZZ - simplywall.st
Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells $235,443.78 in Stock - MarketBeat
Barclays reiterates Jazz Pharmaceuticals stock rating on CNS strength - Investing.com Nigeria
JAZZ or ACAD: Which Is the Better Value Stock Right Now? - Yahoo Finance
S&P 500 Futures Fall in Premarket Trading; Jazz Pharmaceuticals, Live Nation Ent Lead - Barron's
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Victory Capital Management Inc. - MarketBeat
Rhenman & Partners Asset Management AB Cuts Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Revenue Record Puts Focus On Zanidatamab And Valuation - simplywall.st
Neo Ivy Capital Management Takes $1.84 Million Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Deutsche Bank Adjusts Jazz Pharmaceuticals Price Target to $226 From $225, Maintains Buy Rating - marketscreener.com
GW&K Investment Management LLC Sells 17,849 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Mixed Recent Returns And A 5.7% Undervaluation Estimate - simplywall.st
Insider Sell: Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus
JAZZ SEC FilingsJazz Pharmaceuticals Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Jazz Pharmaceuticals plc (JAZZ) reports $1.2 billion Q4 revenue, beats $1.17B estimate - MSN
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Jazz Pharmaceuticals at TD Cowen Conference: Strategic Insights - Investing.com Nigeria
Jazz Pharmaceuticals plc (JAZZ) Reports $1.2 Billion Q4 Revenue, Beats $1.17B Estimate - Finviz
Jazz Pharmaceuticals (NASDAQ: JAZZ) lists option-derived shares for sale via Merrill Lynch - Stock Titan
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After A 36% One Year Share Price Jump - simplywall.st
JAZZ: Record growth, pipeline advances, and rare disease focus drive strong 2026 outlook - TradingView
JAZZ: Record growth, pipeline advances, and new filings drive strong outlook for 2026 - TradingView
JAZZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 3,415 Shares - MarketBeat
Jazz Pharmaceuticals Director Sells 3,415 Shares - TradingView
Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Neena Patil Sells 55,600 Shares - MarketBeat
Jazz Pharmaceuticals (JAZZ) director sells 3,415 shares after option exercise - Stock Titan
Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Patricia Carr Sells 1,117 Shares - MarketBeat
Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) SVP Sells 5,343 Shares of Stock - MarketBeat
Patricia Carr Sells 1,253 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock - MarketBeat
Jazz Pharmaceuticals (JAZZ) CFO granted 11,857 restricted stock units - Stock Titan
Jazz Pharmaceuticals (JAZZ) EVP awarded 9,782 restricted stock units in Form 4 - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) grants 14,822 RSUs to R&D leader - Stock Titan
Jazz Pharmaceuticals (JAZZ) SVP reports share award and open-market sales - Stock Titan
Jazz Pharmaceuticals (JAZZ) CEO receives 44,465 restricted stock units - Stock Titan
Jazz Pharmaceuticals (JAZZ) director receives 1,527-share restricted stock unit grant - Stock Titan
Jazz Pharmaceuticals Insider Sold Shares Worth $1,039,134, According to a Recent SEC Filing - marketscreener.com
Jazz Pharmaceuticals (NASDAQ: JAZZ) EVP Patil sells 55,600 shares - Stock Titan
Jazz Pharmaceuticals (JAZZ) SVP reports RSU grant and tax-driven share sale - Stock Titan
Jazz Pharmaceuticals Reports Record 2025 Revenue, Driven by Xywav Growth - Sleep Review
Jazz Pharmaceuticals (JAZZ) Stock Analysis: Unveiling A 17% Upside Potential For Investors - DirectorsTalk Interviews
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now? - Finviz
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):